Outcome of FDA investigation into Alcon Systane recall by June 30, 2025?
No issues found • 25%
Minor compliance issues • 25%
Major compliance issues • 25%
Recall expanded • 25%
FDA official reports or press releases
Alcon Recalls Systane Lubricant Eye Drops Ultra PF, Lot 10101, Nationwide Due to Fungal Contamination
Dec 24, 2024, 05:31 PM
Alcon Laboratories, based in Fort Worth, Texas, has issued a voluntary recall of a single lot of Systane Lubricant Eye Drops Ultra PF due to potential fungal contamination. The affected product, sold in 25 single-use 'on-the-go' vials, was distributed nationwide to retail and online outlets including Walgreens, CVS, and Target. The recalled lot, identified by lot number 10101 and an expiration date of September 2025, was recalled after a consumer reported finding foreign material in a sealed vial, which was later confirmed to be fungal. The FDA warns that fungal contamination in eye products can lead to serious eye infections, potentially causing partial vision loss, blindness, or in rare cases, life-threatening conditions for immunocompromised individuals. No adverse events related to this recall have been reported to date. Consumers are advised to stop using the recalled eye drops immediately and return them to the place of purchase for a replacement or refund.
View original story
Manufacturing defect • 25%
No specific cause identified • 25%
Supply chain contamination • 25%
Other cause • 25%
No further action • 25%
Fine imposed • 25%
Temporary production halt • 25%
Mandatory product reformulation • 25%
Switch to alternative brands • 25%
Decreased trust in Alcon • 25%
No significant change • 25%
Increased demand for safer packaging • 25%
Other outcome • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
No significant change (+/- 10%) • 25%
Alcon loses market share • 25%
Other outcome • 25%
No significant change • 25%
Alcon gains market share • 25%
Contamination inconclusive • 25%
No contamination found • 25%
Contamination confirmed • 25%
Investigation ongoing • 25%
Increased quality checks • 25%
Product reformulation • 25%
Discontinue product • 25%
No significant changes • 25%